drugset / Trial / NCT05983770

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

NCT05983770

Phase 2 Completed 127 enrolled Eledon Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.

Timeline

Start
2023-08-30
Primary completion
2025-09-11
Completion
2025-09-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tacrolimus Small molecule
Subject Tegoprubart Monoclonal antibody 20 mg/kg Intravenous

Indications